close
close

MicroVention Announces Commercial Availability of LVIS EVO Device in the United States

Posted on by angelo
MicroVention Announces Commercial Availability of LVIS EVO Device in the United States

The LVIS EVO device is equipped to provide enhanced visualization. Credit: MicroVention Inc.

MicroVention, a Terumo subsidiary and neurovascular company, announced the commercial availability of the LVIS EVO intraluminal support device in the United States.

Available in Europe since 2019, the device is designed for the treatment of wide-neck intracranial aneurysms.

Considered the first fully visible coil-assisted intracranial stent in the United States, the LVIS EVO is equipped to provide enhanced visualization, allowing confirmation of wall apposition, and is fully visible under fluoroscopy.

The advanced stent braid design and DFT wire construction contribute to optimized opening and precise placement.

The braid angle of the device has been optimized to improve the opening of the device along its entire length.

Additionally, the device allows for controlled delivery and development, with the ability to cover up to 80% of the device length, ensuring precise placement.

Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive advantage.

Company Profile – Free Sample

Your download email will arrive shortly

We are confident in the unique quality of our business profiles. However, we want you to make the decision that is best for your business, which is why we are offering a free sample that you can download by submitting the form below.

By GlobalData







Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information about your rights regarding your personal data and how you can opt out of future marketing communications. Our Services are intended for business subscribers and you warrant that the email address submitted is your business email address.

Since its European launch, more than 12,000 LVIS EVO units have been sold.

In the United States, the device is indicated for use with neurovascular embolization coils in patients 18 years of age and older for the treatment of wide-neck saccular intracranial aneurysms.

Carsten Schroeder, President and CEO of MicroVention, said: “Today’s announcement underscores MicroVention’s commitment to providing breakthrough solutions for the treatment of hemorrhagic stroke.

“MicroVention continues to lead the way in hemorrhagic and ischemic stroke care. This achievement is a testament to our collaboration with leading physicians around the world. By identifying evolving patient care needs and translating this knowledge into innovative technologies, we are able to save lives and improve outcomes.”

MicroVention said its LVIS EVO line is compatible with its Headway 17 advanced microcatheter and Scepter C and Scepter XC occlusion balloons.

Last year, MicroVention launched the ERIC Recovery Device in the United States for the treatment of ischemic stroke.